Humacyte shares fell 10% in after-hours trading Friday after the Food and Drug Administration said it will require more time to review a proposed treatment for vascular trauma.
Shares were trading around $6.33. The stock has more than doubled in 2024.
The biotechnology company disclosed that the FDA will need more time to review a biologic license application for the acellular tissue engineered vessel in the vascular trauma indication. The acellular tissue engineered vessel trauma program application was submitted to the FDA in December.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments